MedTrace Logo

Evaluate Eribulin ORA in Subjects With Solid Tumors

NCT04013217 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-04-13

No results posted yet for this study

Summary

This is a nonrandomized, open-label, dosed escalation, safety activity, and PK study to determine the MTD and optimal dosing regimen of Eribulin ORA.

Conditions

Interventions

COMBINATION_PRODUCT

Eribulin ORA

Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK

Sponsors & Collaborators

  • Health Hope Pharma

    lead INDUSTRY

Principal Investigators

  • David Cutler, MD · Health Hope Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-29
Primary Completion
2022-03-02
Completion
2022-03-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04013217 on ClinicalTrials.gov